Advertisement

Annals of Hematology

, Volume 98, Issue 3, pp 801–803 | Cite as

Blastic plasmacytoid dendritic cell neoplasm with response to pralatrexate

  • Shuku SatoEmail author
  • Eri Tanaka
  • Yotaro Tamai
Letter to the Editor

Dear Editor,

We encountered a 75-year-old Japanese male patient with a 1-year history of multiple brown nodules appearing on the abdomen and back. Skin lesion biopsies suggested cutaneous T cell lymphoma (CTCL). Computed tomography scans revealed no evidence of lymphadenopathy, and bone marrow specimens revealed no evidence of lymphoma invasion. The patient was treated with 6 cycles of CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) chemotherapy that was administered every 21 days. The nodules initially responded to the CHOP chemotherapy; however, after 3 months, the skin lesions worsened, with multiple, new, larger, brown nodules developing on the back (Fig.  1a). A subsequent skin lesion biopsy of a nodule located on the back revealed recurrent CTCL. Therefore, we attempted a weekly treatment of pralatrexate at a dosage of 30 mg/m 2, intravenously for 3 min, with folate and vitamin B12 supplements. Significant improvement in the tumors was seen after a single course...

Notes

Compliance with ethical standards

Informed consent was obtained from the patient for the treatment. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Petrella T, Facchetti F (2010) Tumoral aspects of plasmacytoid dendritic cells: what do we know in 2009. Autoimmunity 43(3):210–214CrossRefGoogle Scholar
  2. 2.
    Bueno C, Almeida J, Lucio P, Marco J, Garcia R, de Pablos JM, Parreira A, Ramos F, Ruiz-Cabello F, Suarez-Vilela D, San Miguel JF, Orfao A (2004) Incidence and characteristics of CD4(+)/HLA DRhi dendritic cell malignancies. Haematologica 89(1):58–69Google Scholar
  3. 3.
    Julia F, Petrella T, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P, Dereure O, Wetterwald M, d'Incan M, Grange F, Cornillon J, Tertian G, Maubec E, Saiag P, Barete S, Templier I, Aubin F, Dalle S (2013) Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol 169(3):579–586CrossRefGoogle Scholar
  4. 4.
    Feuillard J, Jacob MC, Valensi F, Maynadie M, Gressin R, Chaperot L, Arnoulet C, Brignole-Baudouin F, Drenou B, Duchayne E, Falkenrodt A, Garand R, Homolle E, Husson B, Kuhlein E, Le Calvez G, Sainty D, Sotto MF, Trimoreau F, Bene MC (2002) Clinical and biologic features of CD4 CD56 malignancies. Blood 99(5):1556–1563CrossRefGoogle Scholar
  5. 5.
    Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriondo Atieza A, Arcese W, Beelen DW, Cornilissen JJ, Kroger N, Milone G, Rossi G, Jardin F, Peter C, Rocha V, Sureda A, Mohty M, Dreger P (2013) European Group for blood and marrow transplantation lymphoma, pediatric diseases, and acute leukemia working parties. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 121(3):440–446CrossRefGoogle Scholar
  6. 6.
    Aoki T, Suzuki R, Kuwatsuka Y, Kako S, Fujimoto K, Taguchi J, Kondo T, Ohata K, Ito T, Kamoda Y, Fukuda T, Ichinohe T, Takeuchi K, Izutsu K, Suzumiya J (2015) Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood 125(23):3559–3562CrossRefGoogle Scholar
  7. 7.
    Sugimoto KJ, Shimada A, Yamaguchi N, Imai H, Wakabayashi M, Sekiguchi Y, Izumi H, Ota Y, Komatsu N, Noguchi M (2013) Sustained complete remission of a limited-stage blastic plasmacytoid dendritic cell neoplasm followed by a simultaneous combination of low-dose DeVIC therapy and radiation therapy: a case report and review of the literature. Int J Clin Exp Pathol 6(11):2603–2608Google Scholar
  8. 8.
    Fontaine J, Thomas L, Balame B, Ronger-Savle S, Traulle C, Petrella T, Dalle S (2009) Haematodermic CD4+CD56+ neoplasm: complete remission after methotrexate-asparaginase treatment. Clin Exp Dermatol 34(5):43–45CrossRefGoogle Scholar
  9. 9.
    Yamaguchi M, Kita K, Miwa H, Nishii K, Oda K, Ohno T, Shirakawa S, Fukumoto M (1995) Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76(11):2351–2356CrossRefGoogle Scholar
  10. 10.
    Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, Royer B, Deconinck E, Rowinsky EK, Brooks C, Bardet V, Benet B, Bennani H, Benseddik Z, Debliquis A, Lusina D, Roussel M, Solly F, Ticchioni M, Saas P, Garnache-Ottou F (2015) In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Haematologica 100(2):223–230CrossRefGoogle Scholar
  11. 11.
    Serova M, Bieche I, Sablin M-P, Oronk GJ, Vidaud M, Cvitkovic E, Faivre S, Raymond E (2011) Single agent and combination studies of pralatrexate and molecular correlates of sensitivity. Br J Cancer 104(2):272–280CrossRefGoogle Scholar
  12. 12.
    Justin J. Leitenberger BS, Cindy NB, , Kristel DP, Marbara P, Perter ML, Dan J, Madeleine D (2008) CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol 58(3):480–484CrossRefGoogle Scholar
  13. 13.
    Arranto C, Tzankov A, Halter J (2017) Blastic plasmacytoid dendritic cell neoplasm with transient response to pralatrexate. Ann Hematol 96(4):681–682CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of HematologyShonan Kamakura General HospitalKamakuraJapan
  2. 2.Division of Internal MedicineHayama Heart CenterHayamaJapan

Personalised recommendations